C81.90

Hodgkin lymphoma, unspecified, unspecified site

Hodgkin lymphoma (HL) is a malignant B-cell neoplasm typically characterized by the presence of multinucleated Reed-Sternberg cells within a background of non-neoplastic inflammatory cells. C81.90 is utilized when the clinical documentation does not specify a particular histologic subtype—such as nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted—nor does it specify the primary anatomical site of involvement. This diagnosis often arises during the initial phases of evaluation before biopsy results are fully refined or when diagnostic material is limited. While Hodgkin lymphoma predominantly affects the lymph nodes, particularly in the cervical, supraclavicular, and mediastinal regions, it may also manifest extranodally. Management generally involves multi-agent chemotherapy, occasionally combined with radiation therapy, and is highly responsive compared to many other hematopoietic malignancies.

Clinical Symptoms

Painless swelling of one or more lymph nodes (lymphadenopathy)
Fever of unknown origin (B symptoms)
Drenching night sweats (B symptoms)
Unintentional weight loss of more than 10% body mass over 6 months (B symptoms)
Persistent fatigue and lethargy
Generalized pruritus (intense itching)
Pain in lymph nodes following alcohol consumption
Persistent cough or chest pain (suggesting mediastinal involvement)
Shortness of breath (dyspnea)
Splenomegaly (enlarged spleen)
Hepatomegaly (enlarged liver)
Anorexia and loss of appetite

Common Causes

Epstein-Barr Virus (EBV) infection
Genetic predisposition or family history of Hodgkin lymphoma
Human Immunodeficiency Virus (HIV/AIDS) infection
Post-transplant immunosuppression
Prior autoimmune disorders (e.g., Rheumatoid arthritis, Systemic lupus erythematosus)
Environmental exposures to certain chemicals or pesticides
History of mononucleosis

Documentation & Coding Tips

Transition from unspecified codes to histologically specific codes as soon as pathology results are available.

Example: Patient with persistent supraclavicular lymphadenopathy and 15lb unintentional weight loss. Biopsy confirmed Nodular Sclerosis Hodgkin Lymphoma. Treatment plan involves ABVD chemotherapy. The specific histologic subtype is now documented to replace the preliminary unspecified designation. Risk adjustment increased based on active malignancy status and chemotherapy requirements.

Billing Focus: Identify the specific histologic subtype such as nodular sclerosis or mixed cellularity to move away from C81.90.

Clearly document the anatomical site of lymph node involvement or extranodal manifestations.

Example: Imaging reveals bulky lymphadenopathy in the mediastinum and hilar regions measuring 12cm. Patient has Stage IIA Hodgkin Lymphoma. Documenting the specific intrathoracic site allows for the use of site-specific ICD-10 codes rather than the unspecified site code C81.90. Laterality and specific nodal chains must be documented for billing precision.

Billing Focus: Document nodal regions such as axillary, inguinal, or intrathoracic to satisfy 5th and 6th character specificity.

Include presence or absence of systemic B-symptoms in the diagnostic statement.

Example: Hodgkin lymphoma, unspecified subtype, presenting with drenching night sweats and recurrent fevers up to 101.5F. These systemic symptoms categorize the disease as Stage IIIB. The documentation of constitutional symptoms supports the medical necessity for intensive staging and high-complexity E/M levels.

Billing Focus: Documentation of fevers, weight loss, and night sweats supports higher medical decision making complexity.

Differentiate between initial diagnosis, relapse, and remission status.

Example: Patient with history of Hodgkin lymphoma now presenting with biopsy-proven relapse in the retroperitoneal nodes after 3 years of remission. Documenting the episode of care as a relapse rather than a new primary diagnosis is critical for longitudinal tracking and accurate code selection.

Billing Focus: Status codes for remission versus active disease dictate whether a malignancy code or a history of malignancy code is appropriate.

Capture all related comorbidities that affect chemotherapy or radiation tolerance.

Example: Management of Hodgkin lymphoma complicated by underlying Type 2 Diabetes Mellitus with peripheral neuropathy and Stage 3 Chronic Kidney Disease. Documentation must show how these conditions impact the selection of chemotherapeutic agents and dosage adjustments. The presence of these comorbidities elevates the complexity of the visit.

Billing Focus: Documenting co-occurring chronic conditions supports a High MDM for 99215 coding.

Relevant CPT Codes

99213 - Office or other outpatient visit for the evaluation and management of an established patient
Used for routine follow-up of stable patients under observation or on maintenance therapy.
99214 - Office or other outpatient visit for the evaluation and management of an established patient
Applicable for managing patients with active lymphoma undergoing chemotherapy with associated toxicities.
99215 - Office or other outpatient visit for the evaluation and management of an established patient
Reserved for patients with severe complications, disease progression, or end-of-life discussions.
99204 - Office or other outpatient visit for the evaluation and management of a new patient
Common for the initial consultation of a patient with suspected or newly diagnosed lymphoma.
38510 - Biopsy or excision of lymph node(s); open, deep cervical node(s)
Essential procedure to determine the histology of the lymphoma.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
The standard of care for treating Hodgkin lymphoma.
78815 - Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh
Used for Lugano staging and assessing response via the Deauville scale.
38222 - Diagnostic bone marrow; biopsy(ies) and aspiration(s)
Performed to assess bone marrow involvement in advanced stages.
71250 - Computed tomography, thorax; without contrast material
Standard imaging for detecting thoracic lymphadenopathy.
96415 - Chemotherapy administration, intravenous infusion technique; each additional hour
Required for long multi-drug infusions common in lymphoma protocols.